Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have bee...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & developmental immunology 2010-01, Vol.2010 (2010), p.1-14
Main Authors: Koido, Shigeo, Homma, Sadamu, Hara, Eiichi, Namiki, Yoshihisa, Takahara, Akitaka, Komita, Hideo, Nagasaki, Eijiro, Ito, Masaki, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Format: Article
Language:English
Subjects:
Amino acids
Animals
Antigens, Neoplasm - immunology
Cancer
Cancer therapies
Cancer Vaccines
Cell Fusion - methods
Clinical Trials as Topic
Dendritic Cells - immunology
Hepatology
Humans
Immunology
Lymphocyte Activation
Medical research
Medicine
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Regulation
Review
T-Lymphocytes, Cytotoxic - immunology
Tumor Escape - immunology
Tumor Microenvironment - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.
ISSN:1740-2522
2314-8861
1740-2530
2314-7156
DOI:10.1155/2010/516768